Researchers of Cambridge University overjoyed as NHS approves multiple sclerosis drug for use on patients.
Clinical trials of the drug Alemtuzumab also marketed under the name Lemtrada, have shown great success in minimising the effects of the debilitating neurological disease. Its thought that it could also help sufferers recover from existing damage.
The drug has been developed by Cambridge scientists since 1991 and was approved for the use in people with relapsing – remitting multiple sclerosis by the National Institute for Health and Care Excellence on the 28-05-2014
The head of the department of clinical Neurosciences at Cambridge University Professor Alastair Compston, said “I am delighted that the decision from NICE will make Lemtrada available on the NHS”.
“This brings to a conclusion work involving a number of research groups in Cambridge, stretching back over several decades, which made possible our use of Alemtuzumab in multiple sclerosis”.
The MS society have labelled the announcement as a major step forward. Nick Rijke, director for policy and research at the MS Society, said: “This drug has taken decades to develop, and while it’s not without risk, it’s proven to be a highly effective medicine for people with relapsing remitting MS.”
The researchers are currently working hard to battle against the side effects caused by the drug, this is a problem as one third of patients have developed another autoimmune disease. Which has mainly be targeting the thyroid gland or other tissues however this is still a major breakthrough and great news for Cambridge University researchers.